Cargando…
Overcoming prostate cancer drug resistance with a novel organosilicon small molecule
A major challenge to the treatment of advanced prostate cancer (PCa) is the development of resistance to androgen-deprivation therapy (ADT) and chemotherapy. It is imperative to discover effective therapies to overcome drug resistance and improve clinical outcomes. We have developed a novel class of...
Autores principales: | Zhao, Rui, Ma, Xiaowei, Bai, Lijuan, Li, Xin, Mamouni, Kenza, Yang, Yang, Liu, HongYan, Danaher, Alira, Cook, Nicholas, Kucuk, Omer, Hodges, Robert S., Gera, Lajos, Wu, Daqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604682/ https://www.ncbi.nlm.nih.gov/pubmed/34781084 http://dx.doi.org/10.1016/j.neo.2021.11.006 |
Ejemplares similares
-
Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer
por: Li, Xin, et al.
Publicado: (2021) -
Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models
por: Bai, Lijuan, et al.
Publicado: (2023) -
Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative
por: Zhang, Shumin, et al.
Publicado: (2016) -
New Force-Field for Organosilicon Molecules in the
Liquid Phase
por: Jorge, Miguel, et al.
Publicado: (2021) -
Correction to “New Force-Field for Organosilicon
Molecules in the Liquid Phase”
por: Jorge, Miguel, et al.
Publicado: (2022)